Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Parallel-group, Open-label Phase II Trial of the Immunological Effects of Three Regimens of GX301 Vaccination in Castration-resistant Prostate Cancer Patients Who Have Achieved Response or Disease Stability With First-line Chemotherapy

NCT02293707 is registered in ClinicalTrials.gov with Laboratoires Leurquin Mediolanum as lead sponsor.

NCT NCT02293707
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02293707 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Parallel-group, Open-label Phase II Trial of the Immunological Effects of Three Regimens of GX301 Vaccination in Castration-resistant Prostate Cancer Patients Who Have Achieved Response or Disease Stability With First-line Chemotherapy
Lead sponsor
Laboratoires Leurquin Mediolanum
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2014
Completion date
November 30, 2019
Enrollment
99 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer